Multimodal treatment for resectable epithelial type malignant pleural mesothelioma

World Journal of Surgical Oncology

Yoshihiko Maehara²  Yukito Ichinose¹  Yasuro Fukuyama¹  Chie Ushijima¹  Tatsuro Okamoto¹  Masafumi Yamaguchi²  Ichiro Yoshino² 

[1] Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan;Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan

关键词: cisplatin;    vinorelbine;    gemcitabine;    induction chemotherapy;    hypotonic cisplatin treatment;    Extrapleural pneumonectomy;   

Others  :  1207480
DOI  :  10.1186/1477-7819-2-11

 received in 2003-09-29, accepted in 2004-05-05,  发布年份 2004

【 摘 要 】

Background

Malignant pleural mesothelioma is a rare malignancy. The outcome remains poor despite complete surgical resection.

Patients and methods

Eleven patients with histologicaly proven epithelial type malignant pleural mesothelioma undergoing extrapleural pneumonectomy with systemic chemotherapy and/or radiotherapy before and after surgical resection were retrospectively reviewed.

Results

Ten out of 11 patients underwent complete surgical resection, of these 7 patients had stage I disease. Of these 7 patients, 5 are alive without any recurrence, a 2-year survival rate of 80% was observed in this group. There was no operative mortality or morbidity.

Conclusion

Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma.

【 授权许可】

   
2004 Yoshino et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Connelly RR, Spirtas R, Myers MH, Percy CL, Frameni JF Jr: Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987, 78:1053-1060.
• [2]Harvey JC, Fleischman EH, Kagan AR, Streeter OE: Malignant pleural mesothelioma: a survival study. J Surg Oncol 1990, 45:40-42.
• [3]Takagi K, Tsuchiya R, Watanabe Y: Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer 2001, 31:57-65.
• [4]Sugarbaker DJ, Flores R, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-65.
• [5]Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996, 111:815-826.
• [6]Jaklitsch MT, Grondin SC, Sugarbaker DJ: Treatment of malignant mesothelioma. World J Surg 2001, 25:210-217.
• [7]Garcia JP, Richards WG, Sugarbaker DJ: Surgical treatment of malignant mesothelioma. In In Mastery of cardiothoracic surgery. Edited by Kaiser LR, Kron IL, Spray TL. Lippincott-Raven, Philadelphia, New York; 1998:230-236.
• [8]Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson WS: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25-30.
• [9]Steele JPC, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000, 18:3912-3917.